VolitionRx files patent application for Nu.Q NETs Ebola triage test

Volitionrx

Volitionrx

VNRX

0.00
  • VolitionRx filed a patent application covering use of its Nu.Q NETs test to triage suspected Ebola cases and monitor treatment response.
  • Test measures circulating nucleosomes and neutrophil extracellular traps to flag hyper-inflammation risk tied to septic shock and early mortality.
  • Filing targets field use alongside the company’s CE-marked automated Nu.Q NETs lab assay and a finger-prick lateral flow prototype.
  • VolitionRx is seeking strategic partners to run field trials, scale manufacturing, and deploy the lateral flow test in outbreak zones.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606030812PR_NEWS_USPR_____LN74952) on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.